AgomAb Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for AgomAb Therapeutics (AGMB).

Price Target Range — 3 Quarters

Analyst Consensus — 7 Analysts

7Buy

Consensus RatingOverweight# Analysts7Avg. Consensus PT$38Upside to Avg. PT+347.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 25, 2026	Piper Sandler	Yasmeen Rahimi	Initiate	Overweight	$60
Aug 19, 2026	Cantor Fitzgerald	Yanni Souroutzidis	Initiate	Overweight	—
Jul 23, 2026	B. Riley Securities	William Woods	Initiate	Buy	$34
Jun 22, 2026	HC Wainwright & Co.	Patrick R. Trucchio	Initiate	Buy	$35
Mar 3, 2026	Leerink Partners	Thomas Smith	Initiate	Outperform	$36
Mar 3, 2026	JP Morgan	Anupam Rama	Initiate	Overweight	$32
Mar 3, 2026	Morgan Stanley	Judah Frommer	Initiate	Overweight	$28

Analyst Ratings News

This Agomab Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Analysts change outlook on top names. See all rating changes, including upgrades/downgrades/initiations. Coverage initiated on various stocks.

Avi Kapoor

PRO
Piper Sandler Initiates Coverage On AgomAb Therapeutics with Overweight Rating, Announces Price Target of $60

Piper Sandler analyst Yasmeen Rahimi initiates coverage on AgomAb Therapeutics (NASDAQ:AGMB) with a Overweight rating and announces Price Target of $60.

Benzinga Newsdesk

This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Top analysts change outlook on ALNY, AGMB, BMRN, BEKE, and IONS with ratings and price targets. Check out opinions and coverage on Benzinga.

Avi Kapoor

PRO
Cantor Fitzgerald Initiates Coverage On AgomAb Therapeutics with Overweight Rating

Cantor Fitzgerald analyst Yanni Souroutzidis initiates coverage on AgomAb Therapeutics (NASDAQ:AGMB) with a Overweight rating.

Benzinga Newsdesk

PRO
B. Riley Securities Initiates Coverage On AgomAb Therapeutics with Buy Rating, Announces Price Target of $34

B. Riley Securities analyst William Woods initiates coverage on AgomAb Therapeutics (NASDAQ:AGMB) with a Buy rating and announces Price Target of $34.

Benzinga Newsdesk

This Apple Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Evercore ISI

Avi Kapoor

AgomAb Therapeutics NV

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

AgomAb Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Agomab Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

PRO
Piper Sandler Initiates Coverage On AgomAb Therapeutics with Overweight Rating, Announces Price Target of $60

This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

PRO
Cantor Fitzgerald Initiates Coverage On AgomAb Therapeutics with Overweight Rating

PRO
B. Riley Securities Initiates Coverage On AgomAb Therapeutics with Buy Rating, Announces Price Target of $34

This Apple Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday

People Also Watch

People Also Watch

AgomAb Therapeutics NV

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

AgomAb Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Agomab Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

PROPiper Sandler Initiates Coverage On AgomAb Therapeutics with Overweight Rating, Announces Price Target of $60

This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

PROCantor Fitzgerald Initiates Coverage On AgomAb Therapeutics with Overweight Rating

PROB. Riley Securities Initiates Coverage On AgomAb Therapeutics with Buy Rating, Announces Price Target of $34

This Apple Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday

People Also Watch

People Also Watch

PRO
Piper Sandler Initiates Coverage On AgomAb Therapeutics with Overweight Rating, Announces Price Target of $60

PRO
Cantor Fitzgerald Initiates Coverage On AgomAb Therapeutics with Overweight Rating

PRO
B. Riley Securities Initiates Coverage On AgomAb Therapeutics with Buy Rating, Announces Price Target of $34